Literature DB >> 12508949

Lessons in obesity from transgenic animals.

J R S Arch1.   

Abstract

Many genetic manipulations have created models of obesity, leanness or resistance to dietary obesity in mice, often providing insights into molecular mechanisms that affect energy balance, and new targets for anti-obesity drugs. Since many genes can affect energy balance in mice, polymorphisms in many genes may also contribute to obesity in humans, and there may be many causes of primary leptin resistance. Secondary leptin resistance (due to high leptin levels) can be investigated by combining the ob mutation with other obesity genes. Some transgenic mice have failed to display the expected phenotype, or have even been obese when leanness was expected. Compensatory changes in the expression of other genes during development, or opposing influences of the gene on energy balance, especially in global knockout mice, may offer explanations for such findings. Obesity has been separated from insulin resistance in some transgenic strains, providing new insights into the mechanisms that usually link these phenotypes. It has also been shown that in some transgenic mice, obesity develops without hyperphagia, or leanness without hypophagia, demonstrating that generalised physiological explanations for obesity in individual humans may be inappropriate. Possibly the most important transgenic model of obesity so far created is the Type 1 11beta-hydroxysteroid dehydrogenase over-expressing mouse, since this models the metabolic syndrome in humans. The perspectives into obesity offered by transgenic mouse models should assist clinical researchers in the design and interpretation of their studies in human obesity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12508949     DOI: 10.1007/BF03344050

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  83 in total

Review 1.  5-HT2C receptor modulation and the treatment of obesity.

Authors:  M J Bickerdike; S P Vickers; C T Dourish
Journal:  Diabetes Obes Metab       Date:  1999-07       Impact factor: 6.577

2.  Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.

Authors:  Hiroshi Hirose; Toshihide Kawai; Yukihiro Yamamoto; Matsuo Taniyama; Motowo Tomita; Koichi Matsubara; Yasunori Okazaki; Tatsuya Ishii; Yuko Oguma; Izumi Takei; Takao Saruta
Journal:  Metabolism       Date:  2002-03       Impact factor: 8.694

3.  Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities.

Authors:  Babak Razani; Terry P Combs; Xiao Bo Wang; Philippe G Frank; David S Park; Robert G Russell; Maomi Li; Baiyu Tang; Linda A Jelicks; Philipp E Scherer; Michael P Lisanti
Journal:  J Biol Chem       Date:  2001-12-05       Impact factor: 5.157

4.  Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.

Authors:  J Hara; C T Beuckmann; T Nambu; J T Willie; R M Chemelli; C M Sinton; F Sugiyama; K Yagami; K Goto; M Yanagisawa; T Sakurai
Journal:  Neuron       Date:  2001-05       Impact factor: 17.173

5.  Paternal versus maternal transmission of a stimulatory G-protein alpha subunit knockout produces opposite effects on energy metabolism.

Authors:  S Yu; O Gavrilova; H Chen; R Lee; J Liu; K Pacak; A F Parlow; M J Quon; M L Reitman; L S Weinstein
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

Review 6.  A review of rosiglitazone in type 2 diabetes mellitus.

Authors:  A L Werner; M T Travaglini
Journal:  Pharmacotherapy       Date:  2001-09       Impact factor: 4.705

Review 7.  The role of NPY in metabolic homeostasis: implications for obesity therapy.

Authors:  H A Wieland; B S Hamilton; B Krist; H N Doods
Journal:  Expert Opin Investig Drugs       Date:  2000-06       Impact factor: 6.206

8.  Improved glucose and lipid metabolism in genetically obese mice lacking aP2.

Authors:  K T Uysal; L Scheja; S M Wiesbrock; S Bonner-Weir; G S Hotamisligil
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

Review 9.  Glucocorticoids, 11beta-hydroxysteroid dehydrogenase, and fetal programming.

Authors:  J R Seckl; M Cleasby; M J Nyirenda
Journal:  Kidney Int       Date:  2000-04       Impact factor: 10.612

Review 10.  To eat or to sleep? Orexin in the regulation of feeding and wakefulness.

Authors:  J T Willie; R M Chemelli; C M Sinton; M Yanagisawa
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

View more
  5 in total

Review 1.  Fuel homeostasis and locomotor behavior: role of leptin and melanocortin pathways.

Authors:  G Ceccarini; M Maffei; P Vitti; F Santini
Journal:  J Endocrinol Invest       Date:  2014-12-13       Impact factor: 4.256

2.  Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinase-9.

Authors:  Ghulam Mohammad; Renu A Kowluru
Journal:  J Cell Physiol       Date:  2012-03       Impact factor: 6.384

3.  Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis.

Authors:  Frederic Preitner; Nimesh Mody; Timothy E Graham; Odile D Peroni; Barbara B Kahn
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-10-13       Impact factor: 4.310

4.  Endogenous peroxisome proliferator-activated receptor-gamma augments fatty acid uptake in oxidative muscle.

Authors:  Andrew W Norris; Michael F Hirshman; Jianrong Yao; Niels Jessen; Nicolas Musi; Lihong Chen; William I Sivitz; Laurie J Goodyear; C Ronald Kahn
Journal:  Endocrinology       Date:  2008-07-24       Impact factor: 4.736

5.  Early differentiated CD138(high) MHCII+ IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice.

Authors:  Stéphanie Lacotte; Marion Decossas; Carole Le Coz; Susana Brun; Sylviane Muller; Hélène Dumortier
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.